Therapy with radionuclides, clinical acceptance is overdue
Journal Title: Sultan Qaboos University Medical Journal - Year 2000, Vol 2, Issue 2
Abstract
In this issue, Drs. Bererhi and Constable‘ have published an important paper on the radiation doses received by relatives of patients after radioiodine therapy for thyroid cancer or for hyperthyroid Graves' disease. Basically, they have shown that the radiation doses to the relatives are too small to be an important consideration in radioiodine therapy. The authors are, thus, suggesting much less restrictive precautions, and justifiably so. They have rightly pointed out that in other countries-at least in the United States and in Britain- the regulations are much less demanding as a result of similar earlier studies done in those countries. The US. Nuclear Regulatory Commission (NRC) no longer dic- tates the exact load of radioactive drug within the patient as the limiting factor prior to being discharged from the hospital. Instead, the exposure to the relatives and members of the public is the limiting factor. A patient may be released as long as ‘the effective dose equivalent to any other individual from exposure to the released individual is not likely to exceed 5 millisieverts (0.5 rem).2 It is up to the treating physician to decide whether the risk of exposure to other people is low enough, (under 0.5 rem) before releasing the treated individual from his / her control.2 In fact, in the United States, it is now possible to treat patients with thyroid cancer using 3700-7400 MBq (100-200 mCi) of radioiodine-131 (1311) without admission to hospital. Dr. Bererhi’s article‘ will go a long way towards alleviating the anxieties of the public and physicians in Oman and elsewhere.
Authors and Affiliations
Lamki L M| The University of Texas Medical School, Houston, Texas, USA
Keywords
Related Articles
- EP ID EP13610
- DOI -
- Views 352
- Downloads 17
Successful Salvage Treatment of Resistant Acute Antibody-Mediated Kidney Transplant Rejection with Eculizumab
Antibody-mediated rejection (ABMR) jeopardises short- and long-term transplant survival and remains a challenge in the feld of organ transplantation. We report the frst use of the anticomplement agent eculizumab in Oma...
Heerfordt’s Syndrome Presenting with Recurrent Facial Nerve Palsy Case report and 10-year literature review
Heerfordt’s syndrome is defned as a combination of facial palsy, parotid swelling, uveitis and fever in sarcoidosis cases. Heerfordt’s syndrome as a cause of facial palsy is very rare. We report a case of alternatin...
Central Venous Catheter-Related Infection in Critically Ill Patients
We read with great interest recent studies about infections related to central venous catheter (CVC) and associated risk factors in critically ill postoperative patients evaluated in Iran, Oman and Egypt.1–4 Beigmohamma...
The Value of Programmed Death Ligand 1 Expression in Cancer Patients Treated with Neoadjuvant Chemotherapy
Programmed death ligand 1 (PD-L1) is an inhibitory molecule expressed by cancer cells to supress T-cell activity and escape anti-tumour immunity. The role of PD-L1 in cancer has been studied extensively as it is consider...
A Rhinofacial Conidiobolus coronatus Fungal Infection Presenting as an Intranasal Tumour
Conidiobolomycosis is a rare fungal infection that affects adults in tropical regions. We report a 42-year-old male patient who was referred to the Sulaiman Al Habib Hospital, Dubai, United Arab Emirates (UAE), in 2013 w...